NCT01286272 arm group 277537ab94934b20a53cedd46a4f9d54 [clinicaltrials_resource:NCT01286272/arm-group/277537ab94934b20a53cedd46a4f9d54]
Fludeoxyglucose F-18 [clinicaltrials_resource:0565ed1ded6249b6ecc95ea575d5a954]Positron Emission Tomography with Radiolabeled Targeting Agent [clinicaltrials_resource:1954b6c52c4a2eb5b9ef91f428aa971b]Bortezomib [clinicaltrials_resource:28aaeab2b90fca6cefe8931203d8c24e]Ofatumumab [clinicaltrials_resource:4350d1ec67905d169609f44419c536a2]Laboratory Biomarker Analysis [clinicaltrials_resource:9aa5d807f46d1130b0f9bd7123c53a33]Bendamustine Hydrochloride [clinicaltrials_resource:ac83a709c3db62add18d32ce8f84ab9b]Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma [clinicaltrials:NCT01286272]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01286272 arm group 277537ab94934b20a53cedd46a4f9d54 [clinicaltrials_resource:NCT01286272/arm-group/277537ab94934b20a53cedd46a4f9d54]
Bio2RDF identifier
NCT01286272/arm-group/277537ab94934b20a53cedd46a4f9d54
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 7537ab94934b20a53cedd46a4f9d54
description [clinicaltrials_vocabulary:description]
INDUCTION: Patients receive of ...... y 56 days for up to 4 courses.
identifier
clinicaltrials_resource:NCT01286272/arm-group/277537ab94934b20a53cedd46a4f9d54
title
NCT01286272 arm group 277537ab94934b20a53cedd46a4f9d54
@en
type
label
NCT01286272 arm group 277537ab ...... 537ab94934b20a53cedd46a4f9d54]
@en